{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:44:21Z","timestamp":1790315061637,"version":"4.1.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,9]]},"abstract":"<jats:p>Diffuse malignant peritoneal mesothelioma (MPeM) is rare and arises from peritoneal serosal surfaces. Although it shares similar histomorphology with its counterpart, malignant pleural mesothelioma, etiologies, clinical courses, and therapies differ. Nuclear grading and level of mitoses have been correlated with prognosis in malignant pleural mesothelioma with epithelioid subtype. Whether nuclear grading and level of mitoses correlate with prognosis in MPeM is still unknown. Our study utilizes a 2 tier system incorporating nuclear features and level of the mitoses to stratify cases of MPeM with epithelioid subtype. Fifty-one cases of MPeM with clinical follow-up underwent retrospective microscopic review. From that subset, 46 cases were of epithelioid subtype, which were then stratified into a low-grade or high-grade tier. Survival times were calculated on the basis of Kaplan-Meier analysis. The low-grade tier had higher overall survival with a median of 11.9 years and 57% at 5 years when compared with the high-grade tier with a median of 3.3 years and 21% at 5 years (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.002). Although not statistically significant, the low-grade tier had higher progression-free survival with a median of 4.7 years and 65% at 5 years when compared with the high-grade tier with a median of 1.9 years and 35% at 5 years (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.089). Our study is first to specifically evaluate and correlate nuclear features and level of mitoses with overall survival in MPeM with epithelioid subtype.<\/jats:p>","DOI":"10.1097\/pas.0000000000000696","type":"journal-article","created":{"date-parts":[[2016,7,19]],"date-time":"2016-07-19T16:07:29Z","timestamp":1468944449000},"page":"1243-1248","source":"Crossref","is-referenced-by-count":30,"title":["A Histomorphologic Grading System That Predicts Overall Survival in Diffuse Malignant Peritoneal Mesothelioma With Epithelioid Subtype"],"prefix":"10.1097","volume":"40","author":[{"given":"Kari","family":"Valente","sequence":"first","affiliation":[{"name":"Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron U.","family":"Blackham","sequence":"additional","affiliation":[{"name":"Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Levine","sequence":"additional","affiliation":[{"name":"Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Russell","sequence":"additional","affiliation":[{"name":"Biostatistical Sciences, Wake Forest Baptist Health, Winston-Salem, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos I.","family":"Votanopoulos","sequence":"additional","affiliation":[{"name":"Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Stewart","sequence":"additional","affiliation":[{"name":"Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perry","family":"Shen","sequence":"additional","affiliation":[{"name":"Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim R.","family":"Geisinger","sequence":"additional","affiliation":[{"name":"Department of Pathology, The University of Mississippi Medical Center, Jackson, MS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahussapont J.","family":"Sirintrapun","sequence":"additional","affiliation":[{"name":"Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230922","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/modpathol.2011.146","article-title":"A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma","volume":"25","author":"Kadota","year":"2012","journal-title":"Mod Pathol"},{"key":"R2-20230922","doi-asserted-by":"crossref","first-page":"182","DOI":"10.14694\/EdBook_AM.2013.33.182","article-title":"Peritoneal mesothelioma: the site of origin matters","volume":"33","author":"Kindler","year":"2013","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"R3-20230922","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1245\/s10434-013-3358-y","article-title":"Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis","volume":"21","author":"Magge","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"R4-20230922","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/carcin\/bgt166","article-title":"Molecular pathogenesis of malignant mesothelioma","volume":"34","author":"Sekido","year":"2013","journal-title":"Carcinogenesis"},{"key":"R5-20230922","first-page":"1794","article-title":"Patients with peritoneal mesothelioma lack epidermal growth factor receptor tyrosine kinase mutations that would make them sensitive to tyrosine kinase inhibitors","volume":"24","author":"Kalra","year":"2012","journal-title":"Oncol Rep"},{"key":"R6-20230922","doi-asserted-by":"crossref","first-page":"647","DOI":"10.5858\/arpa.2012-0214-OA","article-title":"Guidelines for pathologic diagnosis of malignant mesothelioma","volume":"137","author":"Husain","year":"2013","journal-title":"Arch Pathol Lab Med"},{"key":"R7-20230922","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/modpathol.2012.39","article-title":"Pleomorphic mesothelioma: report of 10 cases","volume":"25","author":"Ord\u00f3\u00f1ez","year":"2012","journal-title":"Mod Pathol"},{"key":"R8-20230922","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.5858\/2006-130-1654-PSOHPI","article-title":"Prognostic significance of histomorphologic parameters in diffuse malignant peritoneal mesothelioma","volume":"130","author":"Cerruto","year":"2006","journal-title":"Arch Pathol Lab Med"},{"key":"R9-20230922","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/PAT.0b013e3283631cce","article-title":"Diffuse mesothelioma of the peritoneum: a pathologic study of 64 tumors treated with cytoreductive therapy","volume":"45","author":"Lee","year":"2013","journal-title":"Pathology"},{"key":"R10-20230922","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1159\/000333974","article-title":"Cytologic assessment before and after intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis","volume":"40","author":"Loggie","year":"1996","journal-title":"Acta Cytol"},{"key":"R11-20230922","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1177\/000313480106701019","article-title":"Prospective trial for the treatment of malignant peritoneal mesothelioma","volume":"67","author":"Loggie","year":"2001","journal-title":"Am Surg"},{"key":"R12-20230922","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/modpathol.3800067","article-title":"Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers","volume":"17","author":"Trupiano","year":"2004","journal-title":"Mod Pathol"},{"key":"R13-20230922","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1309\/DV1JYBL8LLYYT4J5","article-title":"Cytomorphologic features of primary peritoneal mesothelioma in effusion, washing, and fine-needle aspiration biopsy specimens: examination of 49 cases at one institution, including post-intraperitoneal hyperthermic chemotherapy findings","volume":"128","author":"Patel","year":"2007","journal-title":"Am J Clin Pathol"},{"key":"R14-20230922","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jamcollsurg.2013.12.013","article-title":"Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients","volume":"218","author":"Levine","year":"2014","journal-title":"J Am Coll Surg"},{"key":"R15-20230922","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1245\/ASO.2005.12.001","article-title":"Intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: current status and future directions","volume":"12","author":"Stewart","year":"2005","journal-title":"Ann Surg Oncol"},{"key":"R16-20230922","doi-asserted-by":"crossref","first-page":"4560","DOI":"10.1200\/JCO.2003.04.150","article-title":"Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy","volume":"21","author":"Feldman","year":"2003","journal-title":"J Clin Oncol"},{"key":"R17-20230922","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1245\/s10434-006-9169-7","article-title":"Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma","volume":"14","author":"Yan","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"R18-20230922","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/COC.0b013e3180684181","article-title":"Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for the treatment of malignant peritoneal mesothelioma","volume":"31","author":"Hesdorffer","year":"2008","journal-title":"Am J Clin Oncol"},{"key":"R19-20230922","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/PAT.0000000000000181","article-title":"Diffuse mesothelioma of the peritoneum: correlation between histological and clinical parameters and survival in 73 patients","volume":"46","author":"Liu","year":"2014","journal-title":"Pathology"},{"key":"R20-20230922","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0169-5002(01)00257-4","article-title":"Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma","volume":"32","author":"Ceresoli","year":"2001","journal-title":"Lung Cancer"},{"key":"R21-20230922","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S1055-3207(03)00045-0","article-title":"A review of peritoneal mesothelioma at the Washington Cancer Institute","volume":"12","author":"Sugarbaker","year":"2003","journal-title":"Surg Oncol Clin N Am"},{"key":"R22-20230922","first-page":"195","article-title":"Pharmacodynamic aspects of intraperitoneal cytotoxic therapy","volume":"134","author":"Ceelen","year":"2007","journal-title":"Cancer Treat Res"},{"key":"R23-20230922","doi-asserted-by":"crossref","first-page":"6237","DOI":"10.1200\/JCO.2009.23.9640","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience","volume":"27","author":"Yan","year":"2009","journal-title":"J Clin Oncol"},{"key":"R24-20230922","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.surg.2013.01.001","article-title":"Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma","volume":"153","author":"Alexander","year":"2013","journal-title":"Surgery"},{"key":"R25-20230922","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1016\/j.ejca.2013.05.027","article-title":"Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC)","volume":"49","author":"Baratti","year":"2013","journal-title":"Eur J Cancer"},{"key":"R26-20230922","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1245\/s10434-012-2651-5","article-title":"A novel nomogram for peritoneal mesothelioma predicts survival","volume":"20","author":"Schaub","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"R27-20230922","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1245\/s10434-013-3077-4","article-title":"Malignant peritoneal mesothelioma treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is GLUT1 expression a major prognostic factor? A preliminary study","volume":"20","author":"Hommell-Fontaine","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"R28-20230922","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1177\/000313481408000415","article-title":"Comparison of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with mitomycin or carboplatin for diffuse malignant peritoneal mesothelioma","volume":"80","author":"Shetty","year":"2014","journal-title":"Am Surg"},{"key":"R29-20230922","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1245\/s10434-010-1080-6","article-title":"Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for malignant peritoneal mesothelioma: mitomycin versus cisplatin","volume":"17","author":"Blackham","year":"2010","journal-title":"Ann Surg Oncol"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000478-201609000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T22:23:29Z","timestamp":1695421409000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000478-201609000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000000696","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]}}}